The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging.

The invention provides a compound having the following structure:

D-DT-R,

wherein D is a dextran molecule or a charged dextran molecule having a molecular weight between about 50,000 and about 110,000 Daltons, DT is dodecane tetra-acetic acid (DOTA) or a conjugate base thereof, and R is a radioactive isotope. The invention also provides a method for treating body cavity cancer in a patient afflicted therewith, comprising administering an effective amount of a dextran—dodecane tetraacetic acid—radioactive isotope compound in a pharmaceutically effective vehicle.

The present invention relates to various compositions and methods of using these compositions for imaging natriuretic peptide receptors using, for example, positron emission tomography.

The present invention provides a method for the generation of .sup.223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said .sup.223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted .sup.223Ra solution; iv) loading the .sup.223Ra of the first eluted .sup.223Ra solution onto a strong acid cation exchange resin; and v) eluting the .sup.223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.

The present invention provides a method for the generation of .sup.223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said .sup.223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted .sup.223Ra solution; iv) loading the .sup.223Ra of the first eluted .sup.223Ra solution onto a strong acid cation exchange resin; and v) eluting the .sup.223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.

Gallium-68 generators that are capable of producing gallium-68 from a germanium-68 source material are disclosed. The source material may be a matrix material (e.g., zeolite) in which germanium-68 is isomorphously substituted for central atoms in tetrahedra within the matrix material. Methods for forming gallium-68 generators are also disclosed.

Gallium-68 generators that are capable of producing gallium-68 from a germanium-68 source material are disclosed. The source material may be a matrix material (e.g., zeolite) in which germanium-68 is isomorphously substituted for central atoms in tetrahedra within the matrix material. Methods for forming gallium-68 generators are also disclosed.

The problem to be solved by the present invention is to provide a technique that allows producing a novel radiolabeled compound. The invention is a method for producing a radiolabeled compound, the method including the steps of: irradiating an alloy of a target substance with a radiation beam, to generate two or more radioisotopes from the alloy, and allowing the two or more radioisotopes to migrate into a gas; a step of generating an intermediate label by allowing a first radioisotope, from among the two or more radioisotopes having migrated into the gas, to react with a label precursor; and a step of generating a final label by allowing a second radioisotope different from the first radioisotope, from among the two or more radioisotopes having migrated into the gas, to react with the intermediate label.

The problem to be solved by the present invention is to provide a technique that allows producing a novel radiolabeled compound. The invention is a method for producing a radiolabeled compound, the method including the steps of: irradiating an alloy of a target substance with a radiation beam, to generate two or more radioisotopes from the alloy, and allowing the two or more radioisotopes to migrate into a gas; a step of generating an intermediate label by allowing a first radioisotope, from among the two or more radioisotopes having migrated into the gas, to react with a label precursor; and a step of generating a final label by allowing a second radioisotope different from the first radioisotope, from among the two or more radioisotopes having migrated into the gas, to react with the intermediate label.

The present invention is directed to compositions and methods targeting cells in a subject harboring conditions or at risk for conditions that would benefit from gas-based diagnostic and therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent, including gaseous substances, delivered in combination with the fluorochemical composition.